• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $GDRX

    GoodRx Holdings Inc.

    Subscribe to $GDRX
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings, Inc., through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including telehealth services. The company serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is based in Santa Monica, California.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: goodrx.com

    Recent Analyst Ratings for GoodRx Holdings Inc.

    DatePrice TargetRatingAnalyst
    8/11/2025Strong Buy → Outperform
    Raymond James
    12/4/2024$5.00Neutral
    Mizuho
    8/9/2024$10.00Outperform → Strong Buy
    Raymond James
    5/23/2024$8.00 → $10.00Sector Perform → Outperform
    RBC Capital Mkts
    5/16/2024$10.00Mkt Perform → Outperform
    Raymond James
    4/10/2024$9.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/25/2024$7.50 → $10.00Equal Weight → Overweight
    Wells Fargo
    3/1/2024$7.00 → $10.00Neutral → Overweight
    JP Morgan
    2/26/2024$8.00Outperform
    Leerink Partners
    1/2/2024$8.00 → $4.50Buy → Underperform
    BofA Securities
    See more ratings

    GoodRx Holdings Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Wagner Scott bought $124,806 worth of shares (21,652 units at $5.76) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    12/4/23 4:35:10 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $180,423 worth of shares (30,505 units at $5.91) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/30/23 4:41:35 PM ET
    $GDRX
    EDP Services
    Technology

    Wagner Scott bought $677,475 worth of shares (130,743 units at $5.18) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    11/17/23 7:08:30 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. SEC Filings

    View All

    SEC Form 10-Q filed by GoodRx Holdings Inc.

    10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

    8/6/25 4:20:51 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    8/6/25 4:12:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13D/A filed by GoodRx Holdings Inc.

    SCHEDULE 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    7/3/25 7:23:11 PM ET
    $GDRX
    EDP Services
    Technology

    SEC Form 144 filed by GoodRx Holdings Inc.

    144 - GoodRx Holdings, Inc. (0001809519) (Subject)

    7/3/25 2:33:10 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13D/A filed by GoodRx Holdings Inc.

    SCHEDULE 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    6/9/25 5:12:05 PM ET
    $GDRX
    EDP Services
    Technology

    SEC Form 144 filed by GoodRx Holdings Inc.

    144 - GoodRx Holdings, Inc. (0001809519) (Subject)

    6/6/25 5:05:37 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - GoodRx Holdings, Inc. (0001809519) (Filer)

    6/4/25 4:42:27 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by GoodRx Holdings Inc.

    SCHEDULE 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    5/15/25 10:57:58 AM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by GoodRx Holdings Inc.

    SCHEDULE 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    5/14/25 4:04:49 PM ET
    $GDRX
    EDP Services
    Technology

    SEC Form 10-Q filed by GoodRx Holdings Inc.

    10-Q - GoodRx Holdings, Inc. (0001809519) (Filer)

    5/7/25 4:50:11 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Nabiey Romin covered exercise/tax liability with 1,719 shares and converted options into 4,804 shares, increasing direct ownership by 2% to 137,292 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    8/15/25 6:36:46 PM ET
    $GDRX
    EDP Services
    Technology

    Chief Accounting Officer Nabiey Romin converted options into 12,663 shares and covered exercise/tax liability with 4,531 shares, increasing direct ownership by 6% to 134,207 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    8/8/25 5:15:01 PM ET
    $GDRX
    EDP Services
    Technology

    Director Clark Ian T exercised 17,248 shares at a strike of $4.74, increasing direct ownership by 21% to 100,150 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    7/9/25 5:02:44 PM ET
    $GDRX
    EDP Services
    Technology

    Large owner Spectrum Equity Vii, L.P. converted options into 4,000,000 shares, disposed of 3,989,323 shares and sold $51,226 worth of shares (10,677 units at $4.80) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    7/3/25 6:55:12 PM ET
    $GDRX
    EDP Services
    Technology

    Chief Accounting Officer Nabiey Romin converted options into 12,433 shares and covered exercise/tax liability with 4,449 shares, increasing direct ownership by 7% to 126,075 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    6/9/25 6:15:45 PM ET
    $GDRX
    EDP Services
    Technology

    Large owner Spectrum Equity Vii, L.P. converted options into 4,000,000 shares, disposed of 3,989,323 shares and sold $43,706 worth of shares (10,677 units at $4.09) (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    6/9/25 5:10:39 PM ET
    $GDRX
    EDP Services
    Technology

    Director Clark Ian T was granted 57,050 shares, increasing direct ownership by 221% to 82,902 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    6/4/25 6:51:43 PM ET
    $GDRX
    EDP Services
    Technology

    Director Kennedy Kelly J. was granted 57,050 shares, increasing direct ownership by 106% to 111,062 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    6/4/25 6:51:13 PM ET
    $GDRX
    EDP Services
    Technology

    Director Rey-Giraud Agnes was granted 57,050 shares, increasing direct ownership by 55% to 160,667 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    6/4/25 6:50:46 PM ET
    $GDRX
    EDP Services
    Technology

    Director Hirsch Douglas Joseph was granted 57,050 shares, increasing direct ownership by 37% to 211,388 units (SEC Form 4)

    4 - GoodRx Holdings, Inc. (0001809519) (Issuer)

    6/4/25 6:49:48 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GoodRx downgraded by Raymond James

    Raymond James downgraded GoodRx from Strong Buy to Outperform

    8/11/25 9:45:40 AM ET
    $GDRX
    EDP Services
    Technology

    Mizuho initiated coverage on GoodRx with a new price target

    Mizuho initiated coverage of GoodRx with a rating of Neutral and set a new price target of $5.00

    12/4/24 7:38:07 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx upgraded by Raymond James with a new price target

    Raymond James upgraded GoodRx from Outperform to Strong Buy and set a new price target of $10.00

    8/9/24 7:30:17 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded GoodRx from Sector Perform to Outperform and set a new price target of $10.00 from $8.00 previously

    5/23/24 7:39:11 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx upgraded by Raymond James with a new price target

    Raymond James upgraded GoodRx from Mkt Perform to Outperform and set a new price target of $10.00

    5/16/24 7:34:46 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded GoodRx from Sector Weight to Overweight and set a new price target of $9.00

    4/10/24 7:47:10 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded GoodRx from Equal Weight to Overweight and set a new price target of $10.00 from $7.50 previously

    3/25/24 7:23:59 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx upgraded by JP Morgan with a new price target

    JP Morgan upgraded GoodRx from Neutral to Overweight and set a new price target of $10.00 from $7.00 previously

    3/1/24 7:39:48 AM ET
    $GDRX
    EDP Services
    Technology

    Leerink Partners initiated coverage on GoodRx with a new price target

    Leerink Partners initiated coverage of GoodRx with a rating of Outperform and set a new price target of $8.00

    2/26/24 7:55:54 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx downgraded by BofA Securities with a new price target

    BofA Securities downgraded GoodRx from Buy to Underperform and set a new price target of $4.50 from $8.00 previously

    1/2/24 7:31:38 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    GoodRx Announces Collaboration with Novo Nordisk to Expand Access to Ozempic® and Wegovy® for $499-Per-Month

    Until today, Ozempic® has not been available to eligible self-paying patients at this price GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced that via a collaboration with Novo Nordisk, all strengths of Ozempic® (semaglutide) and Wegovy® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective today. This collaboration significantly lowers the price available on GoodRx for two of the most in-demand GLP-1 medications nationwide, expanding access for those who lack adequate insurance coverage. Today also marks the first time Ozempic® has been made available to patients at this self-pay price.

    8/18/25 9:05:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports Second Quarter 2025 Results

    Second Quarter 2025 Revenue and Adjusted EBITDA Margin in Line with Previous Guidance; Pharma Manufacturer Solutions Revenue Increased 32% Year-Over-Year GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2025. Second Quarter 2025 Highlights Revenue of $203.1 million Net income of $12.8 million; Net income margin of 6.3% Adjusted Net Income1 of $33.9 million; Adjusted Net Income Margin1 of 16.7% Adjusted EBITDA1 of $69.4 million; Adjusted EBITDA Margin1 of 34.2% Net cash provided by operating activities of $49.6 million

    8/6/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Second Quarter 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its second quarter 2025 financial results after U.S. markets close on Wednesday, August 6, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, August 7, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's inve

    7/9/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Launches New Erectile Dysfunction Subscription Service to Simplify Access and Eliminate Treatment Barriers

    The all-in-one solution includes virtual consultation, FDA-approved prescription medication, and discreet home delivery, with no hidden fees, in-person visits, or memberships required GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the launch of a new subscription service for erectile dysfunction (ED). Designed to meet consumers where they are and remove common barriers such as high costs, long wait times, and inconvenience, this all-in-one solution offers a fast, discreet, and affordable option for ED treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610400981/en/ A ne

    6/10/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Launches Community Link to Offer Independent Pharmacies Cost-Plus Pricing

    Community Link allows independent pharmacies to direct contract with GoodRx, manage participation in the company's Integrated Savings Program, and access over 90 brand medication partnership offerings Cost-plus pricing is anchored on NADAC Starting July 1, all independent pharmacies will be opted out of GoodRx's Integrated Savings Program by default GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the launch of GoodRx Community Link. Designed to address the industry challenges that independent community pharmacies face around complex reimbursement models and competitive pressures, Community Link leverages a cost-plus pricing model based on

    6/9/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity

    Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for

    6/5/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx to Launch Direct Contracting for Independent Community Pharmacies

    GoodRx is hosting a webinar on June 3 and 4 to discuss how the company is supporting direct contracting with GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced that it will launch a new offering for independent community pharmacies - GoodRx Community Link - in June 2025. GoodRx Community Link will enable locally owned and operated pharmacies to directly contract with GoodRx on pricing and manage participation in the company's Integrated Savings Programs (ISP). Direct contracts leverage cost-plus models to provide independent pharmacies with more direct control over pricing and favorable margins. GoodRx is committed to helping independent

    5/22/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports First Quarter 2025 Results

    First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025. First Quarter 2025 Highlights Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9% Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4% Net cash provided by operating activities of $9.4 milli

    5/7/25 4:13:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor rel

    4/9/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. Leadership Updates

    Live Leadership Updates

    View All

    GoodRx Appoints Amazon Pharmacy Veteran Laura Jensen as President of Pharma Solutions

    Seasoned industry leader tapped to help pharma reimagine their go-to-market strategies and direct-to-patient models GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. In this role, Laura will lead the company's Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at growing and enhancing innovative partnerships across the pharmaceutical industry. Her deep cross-sector experience uniquely positions her to help revolutionize how patients access and afford their medications through the GoodRx platform. T

    7/28/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Open Sources Lifecycle to Support Innovation in Software Development Velocity and Developer Productivity

    Public release of Lifecycle reflects company's commitment to transparency, innovation, and community collaboration GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced it is open-sourcing Lifecycle, a homegrown development tool designed to improve team velocity, streamline review workflows, and reduce infrastructure overhead. Lifecycle is now available to the public under the Apache 2.0 license, inviting developers and organizations to adopt, contribute to, and build upon the platform. The tool allows engineering, quality assurance, and platform teams to automatically spin up short-lived, isolated environments—known as ephemeral environments—for

    6/5/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

    Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx GoodRx (NASDAQ:GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement, effective immediately. Aaron will be responsible for the management and financial performance of GoodRx's Rx Marketplace offering, working with key retail pharmacy, pharmacy benefit manager (PBM), employer, and manufacturer partners. He will also play a critical role in shaping GoodRx's long-term growth strategy

    3/17/25 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Christopher A. McGinnis as Chief Financial Officer

    Seasoned industry executive brings decades of financial strategy and leadership experience to GoodRx GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced that Christopher A. McGinnis has been appointed as Chief Financial Officer, effective February 4, 2025. Chris brings 30 years of extensive financial experience across the healthcare industry to his new role. Chris will join GoodRx following his role as CEO of CitizensRx, where he led the company in providing pharmacy benefit management services to commercial clients. Before that, Chris held various executive roles at Lumeris / Essence Healthcare, a Medicare Advantage plan and value-based healthca

    2/5/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    WM Technology, Inc. Names Sarah Griffis Chief Technology Officer

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Sarah Griffis as the Company's new Chief Technology Officer, effective January 6, 2025. "I am thrilled to welcome Sarah as our new CTO. She has great experience not just building and leading engineering and tech teams, but also operating in regulated industries like ours," said Doug Francis, Chief Executive Officer at Weedmaps. "I look forward to partnering with her and the rest of our tech org to continue delivering innovative and best-in-class technology solutions to our customers." Prior to joining W

    1/6/25 9:00:00 AM ET
    $GDRX
    $MAPS
    EDP Services
    Technology
    Computer Software: Prepackaged Software

    GoodRx Appoints Healthcare Industry Veteran, Wendy Barnes, as New Chief Executive Officer

    Wendy Barnes, Current CEO of RxBenefits, Brings Extensive Healthcare Management Experience to the Company GoodRx Holdings, Inc. (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced that Wendy Barnes has been appointed as President and Chief Executive Officer, effective January 1, 2025. Wendy brings more than 30 years of leadership experience across the pharmacy and medical benefit industry to her new role. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241216730604/en/Wendy Barnes (Photo: Business Wire) Wendy will join GoodRx following her role as CEO of RxBenefits, where she led the company in

    12/16/24 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Appoints Kelly J. Kennedy to Board of Directors

    Former Chief Financial Officer of The Honest Company brings over 25 years of experience across retail and consumer brands GoodRx (NASDAQ:GDRX), a leading resource for healthcare savings and information, today announced the election of Kelly J. Kennedy to its Board of Directors. Kennedy will serve as a member of the Board's audit committee and fill the seat left vacant by Jacqueline Kosecoff earlier this year. With over 25 years of experience serving in senior financial roles for leading retail and consumer brands, Kennedy brings extensive experience overseeing risk assessment management and financial reporting at large public companies. Currently, Kennedy serves as Chief Financial Offic

    12/22/23 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    Amino Health Announces John Asalone as New CEO; David Vivero Assumes Role of Chairman in CEO Succession

    Amino Health, the leading digital healthcare navigation company, today announced the appointment of John Asalone to the role of Chief Executive Officer. He succeeds David Vivero, the company's visionary founder and CEO, who steps into a new role as Chairman. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231213064342/en/John Asalone, Amino Health CEO (Photo: Business Wire) Asalone, who joined Amino this past August as COO, is a seasoned executive with 20 years of experience scaling software and marketplace companies. Previously the SVP of Growth Verticals at GoodRx (NASDAQ:GDRX), Asalone specializes in bringing consumer-grade ex

    12/13/23 8:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    Established Executive and Milwaukee Business Leader Jim Emling Joins VBA as Executive Chair of the Board of Directors

    Jim Emling, the CEO of Datassential and former long-time president of Milwaukee-based Zywave, has been appointed Executive Chair of the Board of Directors at VBA, the company announced today. "We are delighted to welcome Jim officially to VBA as the Executive Chair," said Michael Clayton, the company's President and CEO. "Jim and I have worked closely together over the last 3 months and his decades of experience scaling high growth software companies combined with his strong ties to the Milwaukee technology sector will be tremendous assets to VBA as we enter our next phase of growth." Emling has deep roots in the Milwaukee technology community. He was the founding CTO of Zywave and serv

    11/28/23 5:00:00 PM ET
    $DH
    $GDRX
    Computer Software: Prepackaged Software
    Technology
    EDP Services

    GoodRx Appoints Dorothy Gemmell as Chief Commercial Officer

    Gemmell to co-lead Pharma Manufacturer Solutions business, oversee GoodRx Health and Provider Mode GoodRx (NASDAQ:GDRX), a leading resource for healthcare savings and information, today announced the appointment of Dorothy Gemmell as Chief Commercial Officer, effective July 3, 2023. Gemmell will work closely with Aaron Crittenden, newly appointed Chief Revenue Officer, and together they will lead the company's Pharma Manufacturer Solutions business, which provides solutions for pharmaceutical and medical device companies. Gemmell brings with her a strong track record leading high-growth teams and building trusted, market-leading healthcare companies that provide solutions to pharmaceuti

    7/10/23 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. Financials

    Live finance-specific insights

    View All

    GoodRx Reports Second Quarter 2025 Results

    Second Quarter 2025 Revenue and Adjusted EBITDA Margin in Line with Previous Guidance; Pharma Manufacturer Solutions Revenue Increased 32% Year-Over-Year GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2025. Second Quarter 2025 Highlights Revenue of $203.1 million Net income of $12.8 million; Net income margin of 6.3% Adjusted Net Income1 of $33.9 million; Adjusted Net Income Margin1 of 16.7% Adjusted EBITDA1 of $69.4 million; Adjusted EBITDA Margin1 of 34.2% Net cash provided by operating activities of $49.6 million

    8/6/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Second Quarter 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its second quarter 2025 financial results after U.S. markets close on Wednesday, August 6, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, August 7, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's inve

    7/9/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports First Quarter 2025 Results

    First Quarter 2025 Revenue In-line; Adjusted EBITDA Margin Beats Previous Guidance; Maintains Full Year 2025 Revenue Guidance Range; Raises Adjusted EBITDA Expectations GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the first quarter of 2025. First Quarter 2025 Highlights Revenue of $203.0 million Net income of $11.1 million; Net income margin of 5.4% Adjusted Net Income1 of $34.4 million; Adjusted Net Income Margin1 of 16.9% Adjusted EBITDA1 of $69.8 million; Adjusted EBITDA Margin1 of 34.4% Net cash provided by operating activities of $9.4 milli

    5/7/25 4:13:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for First Quarter 2025 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading platform for medication savings in the U.S., today announced it will release its first quarter 2025 financial results after U.S. markets close on Wednesday, May 7, 2025. GoodRx management will also hold a conference call and webcast the following morning, Thursday, May 8, 2025 at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor rel

    4/9/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports Fourth Quarter and Full Year 2024 Results

    Fourth Quarter and Full Year 2024 Results Substantially In-line with Previous Guidance GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the fourth quarter and full year of 2024. Fourth Quarter 2024 Highlights Revenue1 of $198.6 million Net income of $6.7 million; Net income margin of 3.4% Adjusted Net Income1 of $34.7 million; Adjusted Net Income Margin1 of 17.5% Adjusted EBITDA1 of $67.1 million; Adjusted EBITDA Margin1 of 33.8% Net cash provided by operating activities of $44.7 million Exited the quarter with over 7 million consumers of pr

    2/27/25 6:05:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced it will release its fourth quarter and full year 2024 financial results before U.S. markets open on Thursday, February 27, 2025. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations websit

    1/30/25 4:05:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports Third Quarter 2024 Results

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $195.3 million Net income of $4.0 million; Net income margin of 2.0% Adjusted Net Income1 of $31.9 million; Adjusted Net Income Margin1 of 16.4% Adjusted EBITDA1 of $65.0 million; Adjusted EBITDA Margin1 of 33.3% Net cash provided by operating activities of $86.9 million Exited the quarter with over 7 million consumers of prescription-related offerings2 "In a world where there is increasing attention on medicin

    11/7/24 6:05:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Third Quarter 2024 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced it will release its third quarter 2024 financial results before U.S. markets open on Thursday, November 7, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations website at https://inve

    10/10/24 5:41:00 PM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Reports Second Quarter 2024 Results

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading prescription savings platform in the U.S., has released its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue1 and Adjusted Revenue1 of $200.6 million Net income of $6.7 million; Net income margin of 3.3% Adjusted Net Income1 of $32.4 million; Adjusted Net Income Margin1 of 16.1% Adjusted EBITDA1 of $65.4 million; Adjusted EBITDA Margin1 of 32.6% Net cash provided by operating activities of $9.7 million Exited the quarter with over 7 million consumers of prescription-related offerings2 "We're proud of the progress we're making against

    8/8/24 6:05:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Announces Date for Second Quarter 2024 Earnings Release and Conference Call

    GoodRx Holdings, Inc. (NASDAQ:GDRX) ("GoodRx" or the "Company"), the leading prescription savings platform in the U.S., today announced it will release its second quarter 2024 financial results before U.S. markets open on Thursday, August 8, 2024. GoodRx management will also hold a conference call and webcast that morning at 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) to discuss the results and the Company's business outlook. To access the conference call, please pre-register using this link. Registrants will receive a confirmation with dial-in details and a unique passcode required to join. The call will also be webcast live on the Company's investor relations website at https://inve

    7/11/24 9:00:00 AM ET
    $GDRX
    EDP Services
    Technology

    GoodRx Holdings Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/14/24 12:29:56 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/13/24 4:30:24 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/12/24 4:02:41 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    11/4/24 11:58:30 AM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by GoodRx Holdings Inc.

    SC 13G/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    10/10/24 11:47:16 AM ET
    $GDRX
    EDP Services
    Technology

    SEC Form SC 13G filed by GoodRx Holdings Inc.

    SC 13G - GoodRx Holdings, Inc. (0001809519) (Subject)

    10/10/24 11:45:33 AM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by GoodRx Holdings Inc.

    SC 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    9/3/24 6:22:25 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by GoodRx Holdings Inc.

    SC 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    6/11/24 7:01:15 PM ET
    $GDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13D/A filed by GoodRx Holdings Inc.

    SC 13D/A - GoodRx Holdings, Inc. (0001809519) (Subject)

    6/11/24 7:00:52 PM ET
    $GDRX
    EDP Services
    Technology

    SEC Form SC 13G filed by GoodRx Holdings Inc.

    SC 13G - GoodRx Holdings, Inc. (0001809519) (Subject)

    5/2/24 4:10:40 PM ET
    $GDRX
    EDP Services
    Technology